Implications of five-year outcomes of PERIGON trial for bioprosthetic aortic valve replacement
- VernacularTitle:PERIGON研究5 年随访结果解读及外科主动脉瓣生物瓣置换的思考
- Author:
Sun PAN
1
;
Chunsheng WANG
1
Author Information
1. Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China
- Publication Type:Journal Article
- Keywords:
Bioprosthesis valve;
surgical aortic valve replacement (SAVR);
structural valve deterioration;
transcatheter aortic valve implantation (TAVI)
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2023;30(01):17-24
- CountryChina
- Language:Chinese
-
Abstract:
For patients with aortic valve disease who require replacement of their native valve, surgical aortic valve replacement (SAVR) has been the standard of care. Due to the hemorrhage and thromboembolic risks of long-term anticoagulation therapy for mechanical prosthesis, bioprosthetic aortic valve replacement (AVR) has a trend to be used in younger patients, which raising the concern for the durability of bioprosthetic valves. The newly published 5-year outcomes of PERIGON trial, with no structural valve deterioration, again demonstrated the favorable durability of the new generation bioprosthetic valves, further providing the evidence of using bioprosthetic AVR in younger patients. At the meantime, the rapid progress of transcatheter aortic valve implantation (TAVI) has brought a new treatment option. For younger patients with low risks, choosing SAVR or TAVI becomes a critical decision. This paper reviews the outcomes of PERIGON trial and its implications to the clinical practice and research of bioprosthetic AVR.
